Skip to main content
. 2019 Feb 26;16:49. doi: 10.1186/s12974-019-1437-0

Fig. 4.

Fig. 4

Laquinimod improves NK cell effector functions. a Killing of B16F10 cells (target) by ex vivo sorted splenic NK cell subsets (effector) from laquinimod- (25 mg/kg) or vehicle-treated mice as assessed by the crystal violet assay. Data are presented as mean ± S.E.M. and are representative of three independent experiments. **P < 0.01, unpaired t test. b Representative FACS plot showing the intracellular IFNγ content in splenic NK cells from laquinimod- or vehicle-treated mice 18 h after IL-12 (1 ng/ml) and IL-18 stimulation (25 ng/ml). Bar graph depicts mean ± S.E.M. pooled from two independent experiments (n = 8/ group). *P < 0.05, unpaired t test. c IFNγ concentrations in the supernatant of IL-12 and IL-18 stimulated splenic NK cells purified from laquinimod- or vehicle-treated mice. The graph depicts mean ± S.E.M. pooled from two independent experiments (n = 8/group), **P < 0.01, unpaired t test. d Metastatic burden in the lungs of preventively laquinimod- (50 mg/kg) or vehicle-treated mice 10 days after i.v. injection of B16F10 melanoma cells (5 × 105) assessed by the quantification of lung nodules and lung weight. Data are presented as mean ± S.E.M. and are representative of four independent experiments. *P < 0.05, **P < 0.01, unpaired t test. e Metastatic burden in the lungs of preventively laquinimod- (50 mg/kg) or vehicle-treated C57BL/6 and AhR−/− mice. Data present mean ± S.E.M. pooled from three independent experiments (12–21 animals/group). *P < 0.05, two-way ANOVA. f Metastatic burden in the lungs of laquinimod- (50 mg/kg) or vehicle-treated mice 19 days after i.v. injection of 2 × 105 B16F10 melanoma cells if treatment was initiated 11 days after melanoma cell transfer